Adial Pharmaceuticals, Inc (ADIL)
ADIL moved a median of 0.00% 30 minutes after news, and -2.14% by the close. How ADIL actually reacts to news — the realized, point-in-time move the market made, measured across 241 labeled events over the last three years with zero look-ahead.
ADIL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 33% | 232 |
| 30-min | 0.00% | 44% | 237 |
| 60-min | -1.34% | 32% | 238 |
| to close | -2.14% | 30% | 239 |
| Middle 50% of ADIL reactions | -2.74% to +1.62% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 241 |
Half of all Adial Pharmaceuticals, Inc news events land between -2.74% and +1.62% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ADIL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ADIL's baseline. Nothing else.
Recent ADIL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis | Press release | GlobeNewswire | — | +11.15% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form DEFA14A ADIAL PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form DEFA14A ADIAL PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | -1.73% | +7.41% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -1.73% | +7.41% | |
| Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +0.24% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.71% | |
| Form DEFA14A ADIAL PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -8.71% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -0.76% | |
| Form DEFA14A ADIAL PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.67% | -0.76% | |
| Form S-3 ADIAL PHARMACEUTICALS, | SEC filing · Form S-3 | SEC EDGAR | +0.36% | +3.23% | |
| Form S-8 ADIAL PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | +0.36% | +3.23% | |
| Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.23% | +1.71% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -2.23% | +1.71% | |
| Form ARS ADIAL PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.99% | +8.79% | |
| Form DEF 14A ADIAL PHARMACEUTICALS, For: Sep 17 | SEC filing · Form DEF | SEC EDGAR | -2.99% | +8.79% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -18.74% | -12.76% | |
| Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | +3.13% | +29.95% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +3.13% | +29.95% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.13% | +29.95% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +4.62% | -3.16% | |
| Form 8-K/A ADIAL PHARMACEUTICALS, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -2.76% | +3.61% | |
| Form PRE 14A ADIAL PHARMACEUTICALS, For: Aug 10 | SEC filing · Form PRE | SEC EDGAR | -2.76% | +3.61% | |
| Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing | Press release | GlobeNewswire | -0.36% | -9.29% | |
| Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing | Press release | GlobeNewswire | +11.21% | +28.45% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +10.94% | -9.42% | |
| Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -2.04% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.04% | |
| Form 10-Q ADIAL PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.04% | |
| Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 | Press release | GlobeNewswire | -0.63% | -2.52% | |
| Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program | Press release | GlobeNewswire | -1.39% | -3.11% | |
| Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial | Press release | GlobeNewswire | -1.10% | -2.18% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | -1.26% | |
| Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans | Press release | GlobeNewswire | +0.34% | -7.65% | |
| Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.09% | -7.11% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | -6.09% | -7.11% | |
| Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.09% | -7.11% | |
| Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement | Press release | GlobeNewswire | -2.46% | -7.66% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.46% | -7.66% | |
| Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement | Press release | GlobeNewswire | -2.12% | +3.39% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -2.12% | +3.39% | |
| Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One | Press release | GlobeNewswire | -0.78% | -9.34% | |
| Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +2.96% | -4.59% | |
| Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 | Press release | GlobeNewswire | -5.49% | -7.49% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | -9.81% | |
| Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement | Press release | GlobeNewswire | -1.18% | -7.76% | |
| Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 | Press release | GlobeNewswire | +7.36% | +4.69% | |
| Form 8-K ADIAL PHARMACEUTICALS, For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -5.20% | |
| Form DEF 14A ADIAL PHARMACEUTICALS, For: Feb 26 | SEC filing · Form DEF | SEC EDGAR | +1.52% | -5.20% | |
| Form PRE 14A ADIAL PHARMACEUTICALS, For: Dec 23 | SEC filing · Form PRE | SEC EDGAR | -1.04% | -6.12% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ADIL section they belong to.
Where else ADIL is measured.
ADIL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Vivakor, Inc. (VIVK) | 243 | -0.30% | 36% |
| IKANG HEALTH CARE GROUP (KANG) | 242 | -0.07% | 44% |
| Dare Bioscience, Inc. (DARE) | 241 | 0.00% | 43% |
| Genprex, Inc. (GNPX) | 241 | -1.17% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Adial Pharmaceuticals, Inc's median reaction calculated?
Every labeled ADIL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 241 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of ADIL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ADIL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.